Phacts for Pharmacists: Diabetes

Edit Answers
1234567891011121314151617181920212223
Across
  1. 2. Absolute contraindication for use of GLP-1 agonist (two words, no spaces)
  2. 4. Glucose dependent insulin secretions
  3. 8. Generic name for a rapid acting insulin
  4. 9. Classification for patients with HbA1c between 5.7% and 6.4%
  5. 11. Known to have active metabolites
  6. 14. Relative contraindication/Precaution for use of DDP4 inhibitors and GLP-1 agonists
  7. 17. The only GLP-1 agonist that is available in an oral formulation
  8. 18. Generic name for a basal insulin
  9. 20. Classification for patients with a HbA1c > 6.5%
  10. 21. Causes glucose independent insulin secretion
  11. 22. The only SGLT2 inhibitor thus far not showing robust benefit for dm patients with CKD, HF, or decrease risk of MACE
  12. 23. Decreases hepatic glucose production
Down
  1. 1. Electrolyte disorder that may be associated with SGLT-2i therapy
  2. 3. Condition associated with symptoms of tachycardia, diaphoresis, tremors, and mental confusion
  3. 5. A GLP-1 agonist that does not have a lead-in dose
  4. 6. A central neuropathy that effects gastric emptying
  5. 7. Must be administered with first bite of carbohydrate containing meal
  6. 10. One of the three predominant symptoms of hyperglycemia
  7. 12. The only DDP-4 inhibitor that does not require a renal dose adjustment
  8. 13. A condition characterized by serum glucose > 600mg/dl, elevated serum osmolality, and urine negative for ketones
  9. 15. A medication class with a U.S. box warning for heart failure NYHA Class III-IV
  10. 16. A medication that should be used with caution in patients with Osteoporosis
  11. 19. Is first line therapy for patients with Type 1 diabetes